PHILADELPHIA, May 4, 2012 /PRNewswire/ -- Shire plc [http://www.shire.com/shireplc/en/home ] (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company,

While pharmacologic agents have a demonstrated efficacy in children with Attention-deficit/hyperactivity disorder (ADHD), some children have suboptimal response to a single pharmacologic agent.

Yale University researchers can't tell you where you left your car keys- but they can tell you why you can't find them.

PHILADELPHIA, Feb.

PHILADELPHIA, February 28, 2011 /PRNewswire-FirstCall/ -- Shire plc, (http://www.shire.com/shireplc/en/home ) (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) approved the use of once-daily INTUNIV(R) (guanfacine) Extended-Release Tablets (http://www.intuniv.com/) as adjunctive therapy to stimulants for the treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents ages 6 to 17 as part of a total treatment program.